Organa Colloidal Silver

Our Colloidal Silver is of a higher purity, non-metallic and becomes crys-talline. The particle size is 40-100 nano meters. Because of the size of the particle, it is able to pass the brain barrier. Our silver can be utilized by the body more readily because of the purity and particle size. It is safer than other colloidal silver manufactures because their particle size is 100 times larger and theirs retains the metallic properties.

$14.95$40.95

Clear selection
Product Description

Silver was employed as a germicide and an antibiotic before modern antibiotics were developed.  It has been used for thousands of years as a medicine and to preserve liquids and foods.  Colloidal silver is one of the most tried and tested supplements, with thousands of clinical lab tests from higher education institutes and clinics around the world.  A high quality colloidal silver will kill pathogens such as E. coli, Salmonella, and Shingella. Independent lab results have also concluded that it is effective against Candida, Staph and even MRSA.

Organa Colloidal Silver is of a higher purity, non-metallic and becomes crystalline. The particle size is 40-100 nano meters. Because of the size of the particle, it is able to pass the brain barrier.

Organa silver can be utilized by the body more readily because of the purity and particle size. It is safer than other colloidal silver manufactures because their particle size is 100 times larger and theirs retains the metallic properties.

Organa Silver is manufactured using a proprietary process known to only a few people worldwide. Because of the uniqueness of our process, our Silver stands alone in its effectiveness as a natural way of helping to overcome sicknesses of many varying varieties.

Organa Colloidal Silver will most likely surpass all the positive benefits that colloidal silver is known for due to our smaller particle size and our unique method of manufacturing. Its particles are crystalline and more efficient and effective.

Medical Research on Colloidal Silver

In an article by scientists Alan Lansdown and Angela Williams, silver resistance in wound care is discussed and they suggest that on the basis of present knowledge, true bacterial resistance to silver is rare.

Lansdown A1, Williams A. Bacterial resistance to silver-based antibiotics. Nurs Times. 2007 Feb 27-Mar 5;103(9):48-9.

This study sought to evaluate the efficacy of a silver-based skin antiseptic against carbapenem-resistant Enterobacteriaceae (CRE). These organisms are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. The results of the study suggest that colloidal silver provides antimicrobial activity against CRE on human skin.

Wiemken, T.L. et al. Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae. Am J Infect Control. 2015 Apr 1;43(4):380-2. doi: 10.1016/j.ajic.2014.12.007. Epub 2015 Feb 7.

This study assessed the safety and efficacy of a topical colloidal silver solution for the treatment of Staphylococcus aureus biofilms in a sheep model. The conclusion of the study was that topical colloidal silver solution has effective antibiofilm activity in Staphylococcus aureus CRS in a sheep model and appears safe.

Rajiv S1, Drilling A, Bassiouni A, James C, Vreugde S, Wormald PJ. Topical colloidal silver as an anti- biofilm agent in a Staphylococcus aureus chronic rhinosinusitis sheep model. Int Forum Allergy Rhinol. 2015 Apr;5(4):283-8. doi: 10.1002/alr.21459. Epub 2015 Jan 30.

This study was created to determine whether colloidal silver has any direct bactericidal effects on Staphylococcus aureus (S. aureus) biofilms. They found that colloidal silver resulted in the reduction of the Staph bacteria by 98.8% and 98.9%.

Goggin R1, Jardeleza C, Wormald PJ, Vreugde S., Colloidal silver: a novel treatment for Staphylococcus aureus biofilms? Int Forum Allergy Rhinol. 2014 Mar;4(3):171-5. doi: 10.1002/alr.21259. Epub 2014 Jan 15.

Nanosilver is assumed to be a new material because of the relatively recent emergence of the term “nano”. However, on close inspection nanosilver materials have a long, 120-year history of relatively safe and regulated use, chiefly in the form of colloidal silver. Historical perspective demonstrates that nanosilver has been intentionally manufactured and adopted commercially across a wide spectrum of everyday applications for many decades. To declare nanosilver materials as “new chemicals” with “unknown properties” that are “potentially harmful” simply on the basis of a change in nomenclature to the term “nano,” and ignoring the accumulated knowledge of its scientific and regulatory heritage demonstrating both safety and efficacy in a wide range of applications, would be a mistake that does not serve the public interest.

Nowack,B., Krug,H.,Height M., 120 Years of Nanosilver History: Implications for Policy Makers. Environ. Sci. Technol. 2011, 45, 1177–1183. pubs.acs.org

Professor Munger at the University of Utah, initiated a human ingestion safety study on a colloidal silver supplement. The abstract for the study states that ingestion of nanosilver particles showed no negative effects on any tested system in the body. The study included 14 day exposures to 10 ppm and up to 35ppm (15 ml/day) silver solution in a double-blind, placebo controlled cross-over phase design. 36 healthy volunteer subjects, underwent complete metabolic, blood and platelet count, urinalysis tests, sputum hyper-responsiveness and inflammation evaluation, physical examinations, vital sign measurements, and magnetic resonance imaging of the chest and abdomen at baseline and at the end of each phase. According to the study authors, “No clinically important changes in any metabolic, hematologic, or urinalysis measure identified were determined. No morphological (or structural) changes were detected in the lungs, heart (cardiac function) or abdominal organs. No changes were noted in sputum reactive oxygen species or in pro-inflammatory cytokines.”
Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28.

In this study published in 2010 in the Journal of Experimental & Clinical Cancer Research, the study authors decided to test colloidal silver against human breast cancer cells. The researchers concluded, “The overall results indicated that the colloidal silver has antitumor activity through induction of apoptosis in MCF-7 breast cancer cell line, suggesting that colloidal silver might be a potential alternative agent for human breast cancer therapy.”

Franco-Molina et al. Antitumor activity of colloidal silver on MCF-7 human breast cancer cells. Journal of Experimental & Clinical Cancer Research 2010, 29:148

Additional Information
size

1 Pint, 1 Quart, 8 oz

parts-per-million

100 ppm, 30 ppm